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__________________________________________________________________________________________ 
ABSTRACT 
Systemic lupus erythematosus (SLE) is an autoimmune disease which causes chronic inflammation and may 
impact various organs. Hematologic abnormality, including thrombocytopenia, is a common clinical manifestation 
in SLE, ranging between 7-30%. Thrombocytopenia in SLE has been proven to correlate with a more active disease 
and a worse prognosis. Most of the time, it gets hard to determine the underlying cause of thrombocytopenia. 
Immature platelet fraction (IPF) examines immature thrombocyte at peripheral blood and can be used to determine 
whether thrombocytopenia happens because of a decreased production or increased peripheral thrombocyte 
destruction. This study was done to evaluate immature platelet fraction value in SLE patients with 
thrombocytopenia. This was a cross-sectional descriptive observational study. Sample was taken from SLE 
inpatients and outpatients at Dr. Hasan Sadikin Bandung Hospital. There were 24 subjects included in this study, 
which counts 7.4% of SLE population. The mean platelet count was 56,870 ±28,933 /mm3. IPF values ranged from 
0.9-3.2%, with median 5.7%. The median IPF in moderate-severe thrombocytopenia group was 7.5%, higher than 
that of mild thrombocytopenia group (4.2%). It can be concluded that IPF values were increased in most SLE 
patients with thrombocytopenia compared to normal population. It suggests that increased platelet destruction 
plays an important role in the pathogenesis of SLE thrombocytopenia. A wide range of IPF values shows 
multifactorial nature of thrombocytopenia causes in SLE patients. 
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ABSTRAK 
Systemic lupus erythematosus (SLE) merupakan penyakit autoimun yang menyebabkan inflamasi kronis dan 
mengenai berbagai organ tubuh. Kelainan hematologi, termasuk trombositopenia, merupakan manifestasi klinis 
yang umum pada SLE, berkisar 7-30%. Trombositopenia pada SLE telah terbukti berhubungan dengan penyakit 
yang lebih aktif dan prognosis yang lebih buruk. Seringkali sulit untuk menentukan penyebab yang mendasari 
terjadinya trombositopenia. Immature platelet fraction (IPF) mengukur trombosit muda di darah perifer dan dapat 
digunakan untuk menentukan apakah trombositopenia terjadi akibat produksi yang kurang atau karena 
peningkatan destruksi perifer trombosit. Penelitian ini diadakan dengan tujuan untuk mengetahui gambaran IPF 
pada SLE dengan trombositopenia. Penelitian ini adalah penelitian yang bersifat observasi deskriptif potong 
lintang. Sampel diambil dari pasien SLE rawat jalan maupun rawat inap di RSUP Dr. Hasan Sadikin Bandung. 
Didapatkan 24 subjek yang diikutsertakan dalam penelitian ini, yaitu sebesar 7,4% dari populasi SLE. Nilai rata-
rata trombosit subjek penelitian sebesar 56.870 ± 28.933 /mm3. Nilai IPF berkisar 0,9 hingga 3,2%, dengan median 
5,7%. Median nilai IPF pada kelompok trombositopenia sedang-berat sebesar 7,5%, lebih tinggi dibanding pada 
kelompok trombositopenia ringan (4,2%). Dapat disimpulkan bahwa IPF meningkat pada sebagian besar pasien 
SLE dengan trombositopenia dibandingkan dengan populasi normal, menunjukkan peningkatan destruksi perifer 
trombosit memegang peranan penting pada patogenesis trombositopenia SLE. Kisaran IPF yang lebar 
menunjukkan penyebab trombositopenia pada SLE yang bersifat multifaktorial. 
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1. Introduction 
 Systemic lupus erythematosus (SLE) is an 
autoimmune disease that causes chronic 
inflammation and affect various organ of the 
body.1 Haematological involvement is common 
and included in both American College of 
Rheumatology (ACR) and Systemic Lupus 
International Collaborating Clinics (SLICC) 
classification criteria for SLE. This includes 
autoimmune haemolytic anemia (AIHA), 
leucopenia, and thrombocytopenia.2,3 
Thrombocytopenia is a common clinical 
manifestation of SLE, ranging from 7-30%.4 
Thrombocytopenia in SLE has been shown to 
be associated with higher disease activity and 
worse prognosis.5,6 However, given the number 
of potential etiologies of thrombocytopenia in 
SLE patients, it is often difficult to determine 
the underlying cause.4 Bone marrow 
examination is usually indicated. This 
procedure has some limitations; it is invasive 
and sometimes difficult to interpret. The 
immature platelet fraction (IPF) is a parameter 
that measures the number of reticulated 
platelets in peripheral blood, using hematology 
analyser Sysmex XE-series. This parameter can 
be used to help determine whether 
thrombocytopenia is secondary to low-platelet 
production or increased platelet turnover.7 
There have been many studies conducted on 
IPF level, such as in ITP, aplastic anemia, and 
post chemotherapy cytopenia. Until recently, 
there has not been any report about IPF in SLE 
patients. The aim of this study is to evaluate IPF 
level in thrombocytopenia SLE. 
 
2. Methods 
This study used a descriptive, cross-
sectional study design. This study was 
conducted in RSUP Dr. Hasan Sadikin. SLE 
patients with thrombocytopenia were enrolled 
in this study from August to December 2016. 
All participants were given informed consent 
and voluntarily participated in this study. The 
study was conducted with the approval by the 
Ethical Committee on Health Research, RSUP 
Dr. Hasan Sadikin Bandung Number 
LB.04.01/A05/EC/268/VIII/2016. 
 
Data Collection Procedures 
Participants were interviewed and asked to 
complete a set of questionnaires that contained 
three sections: (1) Baseline and clinical 
information form; (2) Mex-SLEDAI scoring; 
(3) SLICC/ACR damage index scoring. 
Routine hematological counts and IPF value 
were also measured on the same day.  
(1) Baseline data included age and gender. 
Clinical data included duration of SLE 
diagnosis, organ involvement, ANA pattern 
examination, medical treatment and 
comorbidities. 
(2) Mex-SLEDAI, a modified version of 
SLEDAI, was used to measure disease activity 
of SLE. The score ranges from 0 to 32, with 
higher score imply greater disease activity. 
Patients with score less than 2 are said to have 
clearly inactive disease, those scoring between 
2 and 5 are categorized as probable active, 
while those scoring more than 5 are said to be 
clearly active.8 
(3) SLICC/ACR damage index was 
developed to assess the accumulated damage in 
patients with SLE. This instrument includes 
assessment of 12 organ systems and records 
damage occurring in SLE patients regardless of 
its cause. It may result from previous disease 
activity, from medication, or from intercurrent 
illness. To avoid confusion between active 
inflammation and damage, an item has to be 
present for at least 6 months to be included in 
the damage index.9 
 
3. Results 
There were 24 subjects included in this 
study. Of 24 patients, 14 (58.3%), 7 (29.2%), 
and 3 (12.5%) had mild (platelet counts 
>50,000/mm3, <100,000/mm3), moderate 
(platelet counts >20,000/mm3, ≤50,000/mm3), 
and severe thrombocytopenia (platelet count 
≤20,000/mm3). Patients were divided into 2 
thrombocytopenia groups according to 
severity: mild and moderate-severe.  
Participants’ baseline characteristics are 
summarized in Table 1. The median age was 31 
years old and 91.7% were women.   
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Table 1. Baseline Characteristics 
 
 All 
n=24 
Mild thrombocytopenia 
n=14 
Moderate-severe thrombocytopenia 
n=10 
Age (years), median  
(min – max) 
31 (16 – 64) 33 (22-64) 29 16-36) 
Gender, n (%) 
Male 
Female 
 
2 (8.3) 
22 (91.7) 
 
2 (14.3) 
12 (85.7) 
 
0 (0.0) 
10 (100.0) 
 
 
The clinical characteristics of the patients were shown in Table 2. The median SLE duration was 12 
months. The most detected ANA pattern was homogenous. Besides hematology, patients also had 
other organs involvement: mucocutaneous, musculoskeletal, and renal. Most patients had Mex-
SLEDAI score >5 that showed increased disease activity.  
 
Table 2. Clinical Characteristics 
 
 All 
n=24 
Mild thrombocytopenia 
n=14 
Moderate-severe 
thrombocytopenia 
n=10 
SLE duration (months),  
median (min – max) 
12 (0 – 180) 38 (0-156) 4 (0-180) 
ANA pattern, n (%) 
- Speckled 
- Homogenous 
- Cytoplasmic 
- No data 
 
4 (16.6) 
6 (25) 
1 (4.2) 
13 (54.2) 
 
3 (21.4) 
3 (21.4) 
1 (7.1) 
7 (50.0) 
 
1 (10.0) 
3 (30.0) 
0 (0.0) 
6 (60.0) 
Organ involvement, n (%) 
- Mucocutaneous 
 
- Musculoskeletal 
- Renal 
- Hematology 
 
- Neuropsychiatry 
 
- Vasculitis 
- Serositis 
21 (87.5) 
18 (75) 
18 (75) 
24 (100.0) 
7 (29.2) 
 
2 (8.3) 
2 (8.3) 
14 (100.0) 
 
11 (78.6) 
11 (78.6) 
14 (100.0) 
 
4 (28.6) 
 
2 (14.3) 
0 (0.0) 
7 (70.0) 
 
7 (70.0) 
7 (70.0) 
10 (100.0) 
3 (30.0) 
 
0 (0.0) 
2 (20.0) 
Drugs, n (%) 
- Azathioprine 
- Cyclophosphamide 
 
5 (20.8) 
1 (4.2) 
 
5 (35.7) 
0 (0.0) 
 
0 (0.0) 
1 (10.0) 
Comorbidities, n (%) 
- Sepsis 
- Chronic liver disease 
5 (20.8) 
1 (4.2) 
2 (14.3) 
0 (0.0) 
3 (30.0) 
1 (10.0) 
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MEX-SLEDAI, median (min 
– max) 
- <2  
- 2-5 
 
- >5  
10 (3 – 28) 
 
(n=0) 
(n=5) 
3 (3-5) 
(n=19) 
12 (6-28) 
11 (3-28) 
 
 
 
(n=4)  
3(3-5) 
(n=10) 
14,5 (10-29) 
10 (4-9) 
 
 
 
(n=1) 
4 
(n=9) 
10 (10-19) 
SLICC/ACR damage Index, 
median (min – max) 
1 (0 – 7) 1 (0-7) 2 (0-2) 
 
 
Table 3 shows hematology finding measured by Sysmex XE-series hematology analyzer. Majority of 
patients (79.2%) had anemia. The hemoglobin level in moderate-severe thrombocytopenia group was 
lower than that in the mild group.  
 
Table 3. Hematology Parameter 
 
 All 
n=24 
Mild thrombocytopenia 
n=14 
Moderate-severe 
thrombocytopenia 
n=10 
- Hb (g/dL), mean ± 
SD 
 
 
- WBC (/mm3), 
median (min-max) 
 
 
- Platelet (/mm3), 
mean ± SD 
 
 
- IPF (%), median 
(min-max) 
 
 
- A-IPF (/mm3), 
median (min-max) 
9.5 ± 2.9 
 
 
 
5.920 (380 – 41.320) 
 
 
 
56.870 ± 28.933 
 
 
 
5.7 (0.9 – 32.0) 
 
 
 
2.588 (180-18.792) 
10.3 ± 2.7 
 
 
 
6.130 (1.490 – 14.200) 
 
 
 
4.2 (1.0 – 32.0) 
 
 
 
3.490 (630-18.792) 
8.4 ± 2.8 
 
 
 
5.920 (380 – 41.320) 
 
 
 
7.5 (0.9 – 20.2) 
 
 
 
1.510 (180-4.082) 
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Figure 1. Hemoglobin level in mild and moderate-severe thrombocytopenia groups 
 
 
 
Figure 2. IPF level in mild and moderate-severe thrombocytopenia groups 
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4. Discussion 
This is the first reported study that evaluates 
IPF value in SLE thrombocytopenia patients. 
We found the proportion of SLE patients that 
had thrombocytopenia was 7.4%. This is 
consistent according to known literature, which 
says that it ranges from 7-30%. As reported in 
other studies, we found that the proportion of 
severe thrombocytopenia group was the lowest 
compared to mild and moderate group.10 
Thrombocytopenia could occur in any 
phases of SLE disease courses.  Broadly, it is 
divided into 2 categories. The first one has 
thrombocytopenia as a part of a generalized 
exacerbation of SLE. Usually these patients 
have acute onset, severe, but respond well to 
corticosteroid treatment. The other group has 
more chronic form of thrombocytopenia, less 
related to disease activity and typically less 
responsive to corticosteroid therapy.2 In this 
study we found that majority (58.3%) SLE 
thrombocytopenia patients had disease duration 
of more than 6 months.  
We recorded ANA patterns of the patients. 
From available data, the majority of SLE 
thrombocytopenia patients had homogenous 
pattern. This is consistent with study by 
Ghrahani, which reported that SLE patients 
with homogenous pattern have a higher 
hematology involvement risk.11 
Previous studies found that 
thrombocytopenia in SLE is related with higher 
disease activity.5 In this study we found 75% 
patient had Mex-SLEDAI score >5 that shows 
active disease. In moderate-severe 
thrombocytopenia group, 90% patients had 
active disease; compared with 71.4% patients in 
mild group.  
Immature platelet fraction is good parameter 
that reflects megakaryocytes activity in bone 
marrow. Briggs et all reported the IPF reference 
range in healthy individuals was 1.1-6.1%, with 
a mean of 3.4%.7 In Indonesia, Novita reported 
a reference range of 0.64-3.2%.12 In this study 
we found IPF in SLE thrombocytopenia 
patients ranged from 0.9-3.2% with median 
5.7%. A wide variation in IPF values shows the 
multifactorial causes of thrombocytopenia in 
SLE patients. Median IPF in moderate-severe 
thrombocytopenia group was higher than the 
mild group (7.5% vs 4.2%). This shows a 
negative correlation between platelet count and 
IPF. The lower platelet count, the higher IPF 
value, which shows increased thrombopoiesis 
activity.  
There are several limitations in this study 
that should be considered. First, the current 
study is a descriptive study. There is no analysis 
on factors that affect platelet and IPF level in 
SLE patients. Future studies with multivariate 
analysis are needed. A further limitation of the 
current study is the subjects of this study are 
cross-sectional in nature, only included patients 
who had thrombocytopenia at the time of 
sampling. There was no serial platelet 
examination and outcome follow-up on the 
patients. Another limitation is limited number 
of subjects. For a better analysis, we suggest 
multicentre study involving more patients.  
 
5. Conclusion 
IPF values were increased in most SLE 
patients with thrombocytopenia compared to 
normal SLE population. It suggested that 
increased platelet destruction plays an 
important role in the pathogenesis of SLE 
thrombocytopenia. IPF in moderate-severe 
thrombocytopenia group was higher than the 
mild group and it shows an increase 
thrombopoiesis activity. A wide range of IPF 
values shows multifactorial nature of 
thrombocytopenia causes in SLE patients. IPF 
could be routinely ordered in SLE 
thrombocytopenia patient to determine the need 
of bone marrow examination. 
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